2013
Patient considerations in the use of tapentadol for moderate to severe pain
Vadivelu N, Huang Y, Mirante B, Jacoby M, Braveman FR, Hines RL, Sinatra R. Patient considerations in the use of tapentadol for moderate to severe pain. Drug Healthcare And Patient Safety 2013, Volume 5: 151-159. PMID: 23861601, PMCID: PMC3704302, DOI: 10.2147/dhps.s28829.Peer-Reviewed Original ResearchTapentadol ERTapentadol IRSevere painChronic painOpioid agonistsClinical trialsSide effectsChronic painful diabetic neuropathyMu-opioid receptor agonistCentral nervous system depressantsSimilar pain reliefTraditional opioid agonistsUncontrolled postoperative painSevere acute painSevere chronic painGastrointestinal adverse effectsPainful diabetic neuropathyCommon side effectsNorepinephrine reuptake inhibitorsPost-surgical patientsOpioid receptor agonistsUse of tapentadolDrug Administration approvalMonoamine oxidase inhibitorsPotent opioid agonist
2011
Tapentadol extended-release for treatment of chronic pain: a review
Vadivelu N, Timchenko A, Huang Y, Sinatra R. Tapentadol extended-release for treatment of chronic pain: a review. Journal Of Pain Research 2011, Volume 4: 211-218. PMID: 21887118, PMCID: PMC3160834, DOI: 10.2147/jpr.s14842.Peer-Reviewed Original ResearchLow back painNeuropathic painBack painCancer-related neuropathic painSevere chronic osteoarthritis painCentral nervous system effectsBetter gastrointestinal tolerabilityCancer-related painChronic neuropathic painDiabetic peripheral neuropathySevere acute painChronic osteoarthritis painMajor adverse eventsChronic pain conditionsNervous system effectsNorepinephrine reuptake inhibitionAnalgesic effectivenessEffective analgesiaGastrointestinal intoleranceGastrointestinal tolerabilityOsteoarthritis painAcute painAdverse eventsChronic osteoarthritisPain conditions